Recipharm, the contract development and manufacturing organisation (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organisation.
With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations and customers.
The formation of the ‘Brexit taskforce’ will see Recipharm prioritise its preparations and invest in the necessary capabilities and equipment within its UK and European facilities to ensure seamless operations post March 2019.
To strengthen its organisation ahead of Brexit, Recipharm has plans to recruit more staff in laboratory and regulatory roles to meet the additional analytical, release testing and administration requirements that are expected.
Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization, with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 1400 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm serves over 450 customers from development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US.